More than 3.6 million people are diagnosed with solid malignant tumors every year in the US and EU . The scientific literature has long documented that complete tumor resection and tumor-specific debulking can significantly improve prognoses. But distinguishing healthy from unhealthy tissue has always been difficult during surgical procedures because visual inspection and palpation – the only methods widely available – are limited in their diagnostic capability.

The SurgVision platform technology aims to ultimately provide a robust and accurate solution for surgeons to overcome these issues.

But there is no solution without the right fluorescence tracers.

During the development of tracers, apart from the SurgVision platform technology, SurgVision also provides customization services to help you apply the technology to reach your target, and advice and support to help you achieve confidence in your results.

On screen images kindly provided by University Medical Center Groningen.